{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:52Z","timestamp":1790612152239,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.lanwpc.2023.100925","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T22:53:34Z","timestamp":1697583214000},"page":"100925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study"],"prefix":"10.1016","volume":"42","author":[{"given":"Yue","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieruo","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-0679","authenticated-orcid":false,"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanwpc.2023.100925_bib1","first-page":"S295","article-title":"Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis","volume":"18","author":"Gibofsky","year":"2012","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.lanwpc.2023.100925_bib2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.lanwpc.2023.100925_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1756-185X.13513","article-title":"2018 Update of the APLAR recommendations for treatment of rheumatoid arthritis","volume":"22","author":"Lau","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.lanwpc.2023.100925_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lanwpc.2023.100925_bib5","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2020.1739649","article-title":"Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials","volume":"21","author":"Tanaka","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.lanwpc.2023.100925_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.lanwpc.2023.100925_bib8","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2147\/DDDT.S359501","article-title":"Pharmacokinetics and safety of single and multiple doses of peficitinib (ASP015K) in healthy Chinese subjects","volume":"16","author":"Gao","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.lanwpc.2023.100925_bib9","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanwpc.2023.100925_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/rai2.12043","article-title":"Mechanism-driven strategies for prevention of rheumatoid arthritis","volume":"2","author":"Holers","year":"2022","journal-title":"Rheumatol Autoimmun"},{"key":"10.1016\/j.lanwpc.2023.100925_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","article-title":"A\u00a0structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective","volume":"36","author":"Taylor","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.lanwpc.2023.100925_bib12","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lanwpc.2023.100925_bib13","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lanwpc.2023.100925_bib14","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.lanwpc.2023.100925_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13075-021-02590-z","article-title":"Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis","volume":"23","author":"Tanaka","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lanwpc.2023.100925_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lanwpc.2023.100925_bib17","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lanwpc.2023.100925_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lanwpc.2023.100925_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/art.22552","article-title":"A\u00a0proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response","volume":"57","year":"2007","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.lanwpc.2023.100925_bib20","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lanwpc.2023.100925_bib21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/1756-185X.12723","article-title":"Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy","volume":"19","author":"Li","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.lanwpc.2023.100925_bib22","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.lanwpc.2023.100925_bib23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate","volume":"69","author":"Kivitz","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.lanwpc.2023.100925_bib24","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.4103\/0366-6999.245157","article-title":"Efficacy and safety of tofacitinib in Chinese patients with rheumatoid arthritis","volume":"131","author":"Li","year":"2018","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.lanwpc.2023.100925_bib25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40744-020-00231-6","article-title":"Efficacy and safety of baricitinib in Chinese rheumatoid arthritis patients and the subgroup analyses: results from study RA-BALANCE","volume":"7","author":"Yang","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.lanwpc.2023.100925_bib26","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.lanwpc.2023.100925_bib27","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.lanwpc.2023.100925_bib28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-021-01067-x","article-title":"The safety profile of upadacitinib in patients with rheumatoid arthritis in Japan","volume":"44","author":"Yamaoka","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.lanwpc.2023.100925_bib29","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/mr\/roab069","article-title":"A\u00a0pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.lanwpc.2023.100925_bib30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.semarthrit.2018.07.006","article-title":"A\u00a0pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population","volume":"48","author":"Kivitz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.lanwpc.2023.100925_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lanwpc.2023.100925_bib32","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A\u00a0systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lanwpc.2023.100925_bib33","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/1756-185X.14414","article-title":"Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis","volume":"25","author":"Fang","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.lanwpc.2023.100925_bib34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.lanwpc.2023.100925_bib35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/1756-185X.14570","article-title":"Effectiveness and safety of generic tofacitinib in spondyloarthritis: a real-world retrospective analysis from India","volume":"26","author":"Phatak","year":"2023","journal-title":"Int J Rheum Dis"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606523002432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606523002432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:42:51Z","timestamp":1763001771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606523002432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":34,"alternative-id":["S2666606523002432"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100925","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100925"}}